Status:
COMPLETED
Evaluation of A Novel Methodology in the Assessment of Urethral Function Using [S,S]-Reboxetine in Healthy Volunteers
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
\[S,S\]-Reboxetine will be used to evaluate pharmacodynamic changes in urethral function in healthy volunteers using a novel methodology
Eligibility Criteria
Inclusion
- Healthy female subjects, aged 18-65 years.
- Subjects must be non-pregnant and non-lactating, and be either post menopausal (greater than 1 year without menses), surgically sterilized, or using another acceptable form of contraception.
- Subjects of child bearing potential must have confirmed negative pregnancy tests at screening and prior to commencing all study periods.
Exclusion
- Evidence or history of clinically significant disease (including drug allergies, but excluding untreated, asymptomatic,seasonal allergies at time of dosing).
- Subjects with any clinically significant abnormality following review of laboratory data, urinalysis and physical examination.
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00444548
Start Date
May 1 2007
End Date
July 1 2007
Last Update
June 1 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Hellerup, Denmark, 2900